{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:25:11Z","timestamp":1770884711353,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.clml.2015.07.647","type":"journal-article","created":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T03:24:48Z","timestamp":1438831488000},"page":"e163-e171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"15","author":[{"given":"Kevin B.","family":"Knopf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Divino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaozhu J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shibani","family":"Pokras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Nieset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.07.647_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF02982716","article-title":"Bcr-Abl is a \u201cmolecular switch\u201d for the decision for growth and differentiation in hematopoietic stem cells","volume":"76","author":"Era","year":"2002","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2015.07.647_bib2","series-title":"Gleevec [package insert]","year":"2015"},{"key":"10.1016\/j.clml.2015.07.647_bib3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.2174\/156800912800673202","article-title":"Emerging therapies in chronic myeloid leukemia","volume":"12","author":"Gora-Tybor","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.clml.2015.07.647_bib4","series-title":"Sprycel [package insert]","year":"2014"},{"key":"10.1016\/j.clml.2015.07.647_bib5","series-title":"Tasigna [package insert]","year":"2015"},{"key":"10.1016\/j.clml.2015.07.647_bib6","series-title":"Bosulif [package insert]","year":"2014"},{"key":"10.1016\/j.clml.2015.07.647_bib7","series-title":"Iclusig [package insert]","year":"2014"},{"key":"10.1016\/j.clml.2015.07.647_bib8","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology. Chronic myelogenous leukemia. Version 1.2013. July 5,\u00a02012."},{"key":"10.1016\/j.clml.2015.07.647_bib9","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood-2014-10-567784","article-title":"The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century","volume":"125","author":"Barrett","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.647_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/PPO.0b013e31823dec8d","article-title":"Evolution of therapies for chronic myelogenous leukemia","volume":"17","author":"Santos","year":"2011","journal-title":"Cancer J"},{"key":"10.1016\/j.clml.2015.07.647_bib11","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/cncr.25656","article-title":"Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2015.07.647_bib12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clml.2013.03.018","article-title":"Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options","volume":"13","author":"Jabbour","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2015.07.647_bib13","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.07.647_bib14","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.647_bib15","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome\u2013positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2015.07.647_bib16","unstructured":"Cortes JE, Maru A, De Souza CAA, et\u00a0al. Chronic myeloid leukemia\u2014therapy: new first line options. Paper presented at: 53rd ASH Annual Meeting; San Diego, CA;\u00a02011."},{"key":"10.1016\/j.clml.2015.07.647_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.07.647_bib18","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.647_bib19","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2010.110","article-title":"Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy","volume":"24","author":"Giles","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.07.647_bib20","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1182\/blood.V118.21.4220.4220","article-title":"Health care resource utilization and cost in patients with chronic myeloid leukemia in a privately insured patient population in the United States","volume":"118","author":"Iyer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.647_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/03007990903396469","article-title":"Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2015.07.647_bib22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia","volume":"25","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clml.2015.07.647_bib23","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1185\/03007995.2010.533648","article-title":"Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2015.07.647_bib24","first-page":"331","article-title":"Software for optimal matching in observational studies","volume":"7","author":"Bergstralh","year":"1996","journal-title":"Epidemiology"},{"key":"10.1016\/j.clml.2015.07.647_bib25","unstructured":"US Bureau of Labor Statistics. Consumer Price Indexes (CPI) Program. Available at: http:\/\/www.bls.gov\/cpi\/. Accessed: June 13,\u00a02014."},{"key":"10.1016\/j.clml.2015.07.647_bib26","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","volume":"121","author":"Experts in Chronic Myeloid Leukemia","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.647_bib27","doi-asserted-by":"crossref","unstructured":"Chhatwal J, Mathisen M, Kantarjian H. Are high drug prices for hematologic malignancies justified? A critical analysis. Cancer 2015; http:\/\/dx.doi.org\/10.1002\/cncr.29512. [Epub ahead of print].","DOI":"10.1002\/cncr.29512"},{"key":"10.1016\/j.clml.2015.07.647_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/bmt.2008.90","article-title":"Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?","volume":"42","author":"Ruiz-Arg\u00fcelles","year":"2008","journal-title":"Bone Marrow Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015010794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015010794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T22:37:07Z","timestamp":1599431827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015010794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S2152265015010794"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.07.647","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.07.647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}